GlassScriptPhysician profile
Michele Creamer
NPI 1740782010
$17,596.79
in general payments reported to CMS, 2019-2025
32 companies · $6,726 in 2025
The $6,726 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,419 · 2022: $2,012 · 2023: $3,889 · 2024: $3,551 · 2025: $6,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,165.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,773.30 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $2,627.94 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,967.15 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,345.17 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Axsome Therapeutics, INC. | $1,004.48 | 2023-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $944.21 | 2021-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $896.95 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $861.69 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Corium, LLC | $806.22 | 2022-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $605.70 | 2023-2025 | Ingrezza |
| Lundbeck LLC | $556.94 | 2021-2025 | Rexulti |
| Tris Pharma INC | $486.27 | 2022-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Noven Therapeutics, LLC | $370.45 | 2023-2025 | Xelstrym, Secuado |
| Almatica Pharma LLC | $350.70 | 2023-2025 | Loreev Xr, Gralise |
| Neos Therapeutics, LP | $310.27 | 2022-2025 | Adzenys Xr-Odt, Exxua |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $296.45 | 2022-2025 | Trintellix |
| Bausch Health US, LLC | $293.26 | 2023-2025 | Aplenzin, Wellbutrin |
| Supernus Pharmaceuticals, INC. | $206.36 | 2023-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $191.04 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $187.08 | 2022-2024 | Quviviq |
| Noven Pharmaceuticals, INC. | $145.79 | 2024 | Xelstrym |
| Harmony Biosciences LLC | $103.70 | 2025 | |
| Jazz Pharmaceuticals INC. | $54.20 | 2021-2025 | |
| Eisai INC. | $36.96 | 2022-2024 | |
| Avanir Pharmaceuticals, INC. | $36.42 | 2021 | |
| Ironshore Pharmaceuticals INC. | $27.19 | 2024 | |
| Sunovion Pharmaceuticals INC. | $24.28 | 2021 | |
| Lilly USA, LLC | $22.05 | 2022 | |
| Livanova USA, INC. | $19.35 | 2021 | |
| Indivior INC. | $16.26 | 2021 | |
| Sage Therapeutics, LLC | $14.54 | 2021 | |
| Gilead Sciences, INC. | $14.42 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Creamer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.